Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older.
- You have been prescribed a medication called mavacamten for a heart condition called obstructive hypertrophic cardiomyopathy (a thickening of the heart muscle that blocks blood flow).
- You are willing and able to give your consent to take part in the study.
Who may not be able to join:
- You have previously taken part in, or are currently taking part in, a clinical trial for any medication in the same drug family as mavacamten (called cardiac myosin inhibitors).
- You have already been taking mavacamten for more than 7 days by the time you complete the first survey in the study.
- You are currently enrolled in any other clinical trial, or have been in one within the past six months.
- You had a heart attack that required open-heart bypass surgery within the past three months.
- You had a stroke or a mini-stroke (a brief, stroke-like episode) within the past six months.
- You have moderate-to-severe lung disease that affects your ability to carry out daily activities or breathe normally.
- You had major surgery on your lungs or heart within the past six months.
- You have a major surgery planned in the next three months — for example, joint replacement, abdominal, lung, heart, eye, or brain surgery that requires general anaesthesia and at least one overnight stay in hospital.
- You were hospitalised overnight at the time of screening, or within the two weeks before screening.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Participant Hypertrophic Cardiomyopathy symptoms as assessed by Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ v2,0 - 7-day recall version); Participant physical limitation, symptom stability, symptom frequency, symptom burden, self-efficacy, QoL, and social limitations as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ-23); Participant mavacamten treatment status; Other pharmacological and surgical treatments for obstructive hypertrophic cardiomyopathy (HCM); Participant symptom severity as assessed by self-assessed New York Heart Association (SA-NYHA) functional class; P...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.